~~<i id='F804DFE053'><strike id='F804DFE053'><tt id='F804DFE053'><pre id='F804DFE053'></pre></tt></strike></i>~~

Home» leisure time» leisure time

leisure time

author：knowledge 2025-09-30 20:56:25 Page View：83688

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The drug industry has found itself all alone in Washington
Next article： Bright Health sells Medicare Advantage business to Molina

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Novo Nordisk obesity pill bests Wegovy in early trial

LISELOTTESABROE/AFP/GettyImagesApillbeingdevelopedbyDanishdrugmakerNovoNordiskmayleadtogreaterweight

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

First medicine developed to treat MASH expected to be approved soon

MadrigalCEOBillSiboldsaysthecompanyis"interestedinthepatientswhoaremostinneed."MadrigalPharmaceutica